


PHARMACEUTICAL 2017

GERON CORP Rank 16 of 292









PHARMACEUTICAL 2017



GERON CORP Rank 16 of 292



The relative strengths and weaknesses of GERON CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GERON CORP compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 63% points. The greatest weakness of GERON CORP is the variable Other Revenues, reducing the Economic Capital Ratio by 8.7% points.

The company's Economic Capital Ratio, given in the ranking table, is 262%, being 259% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	116,112
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,869
Liabilities, Non-Current	0
Other Assets	13,954
Other Compr. Net Income	160
Other Expenses	83
Other Liabilities	0
Other Net Income	0
Other Revenues	7,354
Property and Equipment	183
Research and Development	18,047
Selling, General and Administrative Expense	18,761

Output Variable	Value in 1000 USD
Assets	130,249
Liabilities	7,869
Expenses	36,891
Revenues	7,354
Stockholders Equity	122,380
Net Income	-29,537
Comprehensive Net Income	-29,457
Economic Capital Ratio	262%

